Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Drug-Linker Conjugates for ADC
    (4)
  • TLR
    (2)
  • Adenosine Receptor
    (1)
  • Apoptosis
    (1)
  • Aryl Hydrocarbon Receptor
    (1)
  • Bcr-Abl
    (1)
  • CCR
    (1)
  • Calcium Channel
    (1)
  • Cannabinoid Receptor
    (1)
  • Others
    (35)
Filter
Search Result
Results for "

st 4

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    59
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Recombinant Protein
    10
    TargetMol | Recombinant_Protein
  • Antibody Products
    6
    TargetMol | Antibody_Products
Adenosine receptor antagonist 4
T21620133240-06-9In house
Adenosine receptor antagonist 4 is an adenosine receptor antagonist.
  • Inquiry Price
Size
QTY
MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate
MC-Val-Cit-PAB-Amide-TLR7 agonist 4
T744682413016-49-4In house
MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate is a conjugate of MC-Val-Cit-PAB-Amide and TLR7 agonist 4, used in cancer research.
  • Inquiry Price
Size
QTY
TargetMol
MC-Val-Cit-PAB-Amide-TLR7 agonist 4 TFA
MC-Val-Cit-PAB-Amide-TLR7 agonist 4 TFA(2413016-49-4 Free base)
T74468L
MC-Val-Cit-PAB-Amide-TLR7 agonist 4 TFA is the trifluoroacetate form of MC-Val-Cit-PAB-Amide-TLR7 agonist 4. MC-Val-Cit-PAB-Amide-TLR7 agonist 4 is a HER2-TLR7 and HER2- TLR8 immune agonist complexes with potential antitumor activity by activating the TLR7 and TLR8 signaling pathways and enhancing immune responses.
  • Inquiry Price
Size
QTY
AHR antagonist 4
T102712242465-58-1In house
AHR antagonist 4 is a potent aryl hydrocarbon receptor (AHR) antagonist(example 293; IC50: 82.2 nM).It has anti-cancer effects.
  • Inquiry Price
8-10 weeks
Size
QTY
AST 487
NVP-AST 487
T4053630124-46-8
AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.
  • Inquiry Price
Size
QTY
CB1 antagonist 4
T85111253641-65-4
CB1 antagonist 4 is an antagonist of cannabinoid receptor type 1 (CB1), with potential for the treatment of obesity and type 2 diabetes.
  • Inquiry Price
Size
QTY
Calcium Channel antagonist 4
T77711687574-49-8
Calcium Channel antagonist 4 is a voltage-gated calcium channel inhibitor (IC50 : 5-20 μM).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
GLP-1 receptor agonist 4
T114051187061-62-6
GLP-1 receptor agonist 4 is a glucagon-like peptide-1 receptor (GLP-1R) agonist with an EC50 of 64.5 nM, and is utilized in diabetes treatment research.
  • Inquiry Price
Size
QTY
CCR2 antagonist 4
Teijin compound 1
T13114226226-39-7
CCR2 antagonist 4 (Teijin compound 1) is a potent and specific CCR2 antagonist with IC50 values of 180 nM and 24 nM for CCR2 inhibition and MCP-1-induced chemotaxis inhibition, respectively.
  • Inquiry Price
6-8 weeks
Size
QTY
FPR Agonist 43
T17005903895-98-7
FPR Agonist 43 is a dual agonist of formyl peptide receptor 1 and formyl peptide receptor 2 (FPR2) ALX.
  • Inquiry Price
Size
QTY
CCR2 antagonist 4 hydrochloride
Teijin compound 1 hydrochloride
T192301313730-14-1
CCR2 antagonist 4 hydrochloride is a specific CCR2 antagonist (IC50s: 180 nM for CCR2b). It potently inhibits MCP-1-induced chemotaxis (IC50: 24 nM).
  • Inquiry Price
1-2 weeks
Size
QTY
H3R antagonist 4
T200389
H3R antagonist 4 (compound 11l) serves as a dual inhibitor of cholinesterases and histamine H3 receptors (H3R), demonstrating IC50 values of 7.04 μM (eeAChE), 9.73 μM (hAChE)(reversible), and 1.09 nM (H3R). It effectively inhibits both self and Cu2+-induced Aβ1-42 aggregation at 95.48% and 88.63%, respectively, and degrades Aβ1-42 protofibrils with 80.16% and 89.30% efficiency under similar conditions. Additionally, H3R antagonist 4 possesses the chelating capability for biometals Cu2+, Zn2+, Al3+, and Fe2+. It significantly reduces tau protein hyperphosphorylation induced by Aβ1-42, inhibits RSL-3 induced apoptosis and ferroptosis in PC12 cells, and shows optimal blood-brain barrier permeability and intestinal absorption characteristics in hCMEC D3 and hPepT1-MDCK cells, respectively. Moreover, the compound improves learning and memory impairments in an Alzheimer's mouse model induced with scopolamine.
  • Inquiry Price
Size
QTY
KOR agonist 4
T205240
KOR agonist 4 (compound 39) is an agonist targeting the κ opioid receptor (Kappa Opioid Receptor) and activates G protein signaling. It has an EC50 of 14 nM and an Emax of 83% for binding to GTPγS. This compound demonstrates moderate to high intrinsic clearance in human liver cells and shows selectivity for the κ opioid receptor over the μ (MOR) and δ (DOR) opioid receptors by factors of 60 and 810, respectively. KOR agonist 4 is useful for research into central nervous system (CNS) disorders.
  • Inquiry Price
Size
QTY
APJ receptor agonist 4
T395872135515-67-0
APJ Receptor Agonist 4 is a potent, orally active apelin receptor (APJ) agonist, demonstrating an EC50 of 0.06 nM and a Ki of 0.07 nM. It exhibits excellent pharmacokinetic profiles in rodent heart failure (HF) models and has shown an acceptable safety profile in preclinical toxicology studies. This compound effectively improves cardiac function, making it valuable for research into HF disease.
  • Inquiry Price
Size
QTY
TLR7/8 agonist 4 hydroxy-PEG10-acid
TLR7 8 agonist 4 hydroxy-PEG10-acid
T399682388520-17-8
TLR7 8 agonist 4 hydroxy-PEG10-acid [compound 9] is a drug-linker conjugate used in antibody-drug conjugates (ADC), exhibiting remarkable antitumor activity. It utilizes TLR7 8 agonist 4, a potent activator of TLR7 8, linked to hydroxy-PEG10-acid via a cleavable bond, demonstrating promising pharmaceutical potential in ADC-based therapeutics.
  • Inquiry Price
Size
QTY
TLR7/8 agonist 4 TFA
T399692388520-34-9
TLR7 8 agonist 4 TFA (compound 41) is a highly potent TLR7 8 agonist demonstrating significant anti-cancer activity.
  • Inquiry Price
Size
QTY
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride
TLR7 8 agonist 4 hydroxy-PEG10-acid hydrochloride
T399702388520-36-1
TLR7 8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a drug-linker conjugate used in antibody-drug conjugates (ADCs) with high tumor efficacy. It consists of TLR7 8 agonist 4, a potent TLR7 8 agonist, linked to the ADC linker hydroxy-PEG10-acid, which can be cleaved.
  • Inquiry Price
Size
QTY
NMDA receptor antagonist 4
T603061607589-56-9
NMDA receptor antagonist 4 (IIc) is an uncompetitive, voltage-dependent, orally active NMDAR blocker with an IC50 of 1.93 μM. It shows positive predicted blood-brain-barrier (BBB) permeability and can be used in Alzheimer's disease research[1].
  • Inquiry Price
6-8 weeks
Size
QTY
Wnt/β-catenin agonist 4
T60803912784-79-3
Wnt β-catenin agonist 4 is an agonist of Wnt that activates Wnt β-catenin signaling and directs signaling.
  • Inquiry Price
6-8 weeks
Size
QTY
EP4 receptor antagonist 4
T60840691869-12-2
EP4 receptor antagonist 4 is an agonist of EP4 receptor (human pEC 50 = 6.3) [1].
  • Inquiry Price
6-8 weeks
Size
QTY
TLR7/8 agonist 4
T608942388520-33-8
TLR7 8 agonist 4 (compound 41) is a potent TLR7 8 agonist with demonstrated anti-cancer activity [1].
  • Inquiry Price
6-8 weeks
Size
QTY
SSTR4 agonist 4
T609112747928-27-2
SSTR4 agonist 4 is a potent SSTR4 agonist with potential applications in pain research. SSTR4 agonists demonstrate efficacy in rodent models of pain associated with acute and chronic anti-peripheral nociceptive and anti-inflammatory activity. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, regions involved in memory and learning, and in Alzheimer's disease pathology [1].
  • Inquiry Price
10-14 weeks
Size
QTY
Androgen receptor antagonist 4
T60988354815-43-3
Androgen receptor antagonist 4 (Compound AT2) exhibits anticancer activities by potently antagonizing AR transcriptional activity, inhibiting downstream AR target genes, and blocking DHT-induced nuclear translocation of AR. It is an antagonist of the androgen receptor (AR) with an IC50 of 0.15 μM [1].
  • Inquiry Price
6-8 weeks
Size
QTY
cxcr2 antagonist 4
T61447
CXCR2 antagonist 4 (compound 7) is a highly potent inhibitor of CXCR2 with an IC50 of 0.13 μM and effectively inhibits the CXCL8-induced cytosolic calcium increase with an IC50 of 27 μM, demonstrating promising potential for anticancer research [1].
  • Inquiry Price
10-14 weeks
Size
QTY